Why Is REVVITY INC (RVTY) Stock Up Today?

RVTY stock is up 6.93% at $137.40 as of the latest trade, driven by a series of high-profile company presentations and analyst activity. The stock opened at $128.67 and reached an intraday high of $139.15, with volume of 0.7 million shares, slightly above the 3-month average. Analyst updates and recent strategic moves by Revvity are fueling investor interest.

What Happened

Revvity, Inc. presented at two major healthcare conferences in recent days: the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 and the 2026 Global Healthcare Conference on September 15. These appearances likely increased visibility for the company and reinforced its strategic focus on growth areas such as preclinical research and human cell models. In addition, UBS raised its price target to $140 and RBC Capital initiated coverage with a Sector Perform rating and a $135 price target. KeyBanc also raised its price target to $165. These analyst actions, combined with Revvity’s recent acquisition of French biotech firm Human Cell Design, have positioned the stock as a beneficiary of the GLP-1 drug development boom.

What The Data Shows

The stock is trading near its 52-week high of $133.00, having printed 37 fresh 52-week highs on September 15. The price action reflects strong momentum, with the stock climbing from its open and maintaining elevated levels throughout the session. Revvity’s fundamentals show a market cap of $13.9B, a P/E of 61.4, and revenue growth of 4.1% in the trailing twelve months. The company has a net margin of 8.2% and a beta of 1.09. Recent insider transactions include a $9K sale by VP and CAO Anita Gonzales on July 20. No insider purchases have been reported in the last 90 days.

What To Watch

Investors should monitor Revvity’s upcoming earnings report, if scheduled, and continued analyst coverage. The stock’s performance in the context of broader healthcare sector trends and its execution on strategic initiatives will be key factors.